INTRODUCTION — Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, and activities.
The terminology, epidemiology, and pathogenesis of ASD will be reviewed here. Surveillance and screening, clinical features, diagnosis, and management of ASD are discussed separately. (See "Autism spectrum disorder: Surveillance and screening in primary care" and "Autism spectrum disorder: Clinical features" and "Autism spectrum disorder: Evaluation and diagnosis" and "Autism spectrum disorder in children and adolescents: Overview of management".)
TERMINOLOGY — The terminology and diagnostic criteria for ASD vary geographically. The Diagnostic and Statistical Manual of Mental Disorders (DSM) is used predominantly in the United States and was updated in 2013 (DSM-5) [1]. The World Health Organization International Classification of Diseases, 10th revision (ICD-10) is used in other countries throughout the world [2]. A version of the 11th revision (ICD-11) was released in 2018 to begin preparations for implementation [3]; use by member states is anticipated in 2022.
DSM-5 — The DSM-5 diagnosis of ASD is characterized by [1]:
●Persistent deficits in social communication and interaction (eg, deficits in social reciprocity; nonverbal communicative behaviors; and skills in developing, maintaining, and understanding relationships), and
●Restricted, repetitive patterns of behavior, interests, or activities
These symptoms must be present in early development. However, because symptoms may not be apparent until social demands exceed limited capacities, no age threshold for "early development" is specified.
The diagnosis of ASD is qualified by a number of specifiers, including three levels of severity (rated separately for social communication and restricted, repetitive behaviors) and the presence or absence of associated conditions (eg, intellectual impairment, language impairment, etc) [1]. (See "Autism spectrum disorder: Evaluation and diagnosis", section on 'Diagnostic criteria'.)
ICD — In contrast to DSM-5, which uses ASD as a single diagnostic label, the ICD-10 classifies ASD as "pervasive developmental disorders" and includes several subtypes, including childhood autism, atypical autism, and Asperger syndrome (table 1), among others [2]. The ICD-10 system provides two sets of guidelines: 1) clinical descriptions and diagnostic guidelines and 2) diagnostic criteria for research.
The version of ICD-11 released in 2018 (anticipated for use in 2022) indicates that the ICD-11 classification of ASD will be similar to that in DSM-5 [3]. ASD is the "parent" term, which is further characterized by presence or absence of a disorder of intellectual development and/or impairment or absence of functional language. The ICD-11 clinical descriptions and diagnostic guidelines and diagnostic criteria for research are not yet available. The ICD-10 clinical descriptions and diagnostic guidelines should be used until January 2022, when the transition to ICD-11 is scheduled to occur.
EPIDEMIOLOGY
Prevalence — Estimates of the prevalence of ASD vary with study methodology and the population that is evaluated. The overall prevalence of ASD in Europe, Asia, and the United States ranges from 2 to 25 per 1000, or approximately 1 in 40 to 1 in 500 [4-19].
Three national databases are used to estimate ASD prevalence in the United States:
●The Autism and Developmental Disabilities Monitoring (ADDM) Network identifies ASD through screening and abstraction of existing health and education records among eight-year-old children at selected study sites. For 2018, the surveillance case definition included any of the following: an ASD diagnostic statement in an evaluation, a special education classification of ASD, or an ASD International Classification of Diseases code [16]. The previous case definition required documentation of behaviors consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. In a study that compared the previous and updated case definitions, the updated case definition yielded a similar prevalence for 2014 and a slightly lower prevalence for 2016 [20].
In 2018, the estimated prevalence was 23 per 1000 (1 in 44) eight-year-old children overall, 1 in 27 males, and 1 in 113 females [16]. This prevalence is increased compared with previous years; however, the surveillance catchment areas, case definition, and data collection process changed in 2018. The prevalence estimates varied widely by site. Although the prevalence was similar across racial and ethnic groups, it was higher among American Indian including Alaska Native children than non-Hispanic White children (29 versus 21.2 per 1000).
●The Early ADDM Network identifies ASD through screening and abstraction of existing health and education records among four-year old children at selected study sites. The Early ADDM Network uses the same case definition as the ADDM Network described above (which was changed in 2018).
In 2018, the estimated prevalence was 17 per 1000 (1 in 59) four-year-old children overall, 1 in 39 males, and 1 in 143 females [17]. Prevalence estimates varied widely by site and by race/ethnicity (12.9 per 1000 among non-Hispanic White children, 16.6 per 1000 non-Hispanic Black children, 21.1 per 1000 among Hispanic children, and 22.7 among Asian/Pacific Islander children). Surveillance at age four years may include children with more severe symptoms or coexisting conditions (eg, intellectual disability).
●The National Health Interview Survey (NHIS) estimates the prevalence of ASD in children age 3 through 17 years according to parent report of a physician diagnosis [14]. In the 2016 NHIS, the estimated prevalence of ASD was 25 per 1000 (95% CI 22.3 to 28.1 per 1000); approximately 1 in 40 children overall, 1 in 26 males, and 1 in 93 females.
The prevalence of ASD has increased over time, particularly since the late 1990s [16,21,22]. Systematic reviews of epidemiologic studies suggest that changes in case definition and increased awareness account for much of the apparent increase [21,23-26]. Other factors that may play a role include earlier detection, availability of more specialized developmental services, diagnostic substitution (ie, increases in prevalence of ASD accompanied by decreases in the prevalence of learning disorders, developmental language disorder, and/or intellectual disability [ID]), as well as a true increase in prevalence [9,23,25,27-33].
Male-to-female ratio — ASD is three to four times more common in males than females [16,17,34,35]. In a systematic review of 54 studies including >13,700,000 patients, the overall male-to-female ratio was 4.2 (95% CI 3.8-4.6) [34]. However, in higher quality studies and in studies that screened the general population for cases of ASD, the male-to-female ratio was closer to 3, suggesting that ASD may be underdiagnosed in females.
Rate in siblings — The estimated prevalence of ASD in siblings of a child with ASD who does not have an associated medical condition or syndrome is approximately 10 percent (range 4 to 14 percent) [36-39]. However, in some studies, the prevalence of ASD in siblings of children with ASD is as high as 20 percent [36,40,41].
Younger male siblings of a child with ASD are more often affected than younger female siblings, but the risk of recurrence appears to be increased when the index patient is a female. An administrative database study evaluated the recurrence of ASD among children in >1.5 million families with two children age 4 to 18 years between 2008 and 2016 [41]. The overall prevalence of ASD was 1.25 percent. Among the families in which the older child had ASD, the risk of recurrence varied as follows according to the sex of the siblings:
●Younger brothers of females with ASD – 17 percent
●Younger brothers of males with ASD – 13 percent
●Younger sisters of females with ASD – 8 percent
●Younger sisters of males with ASD – 4 percent
The 2013 American College of Medical Genetics and Genomics practice guideline provides the following risks for ASD in siblings of children with ASD without an identifiable etiology: 7 percent if the affected child is female, 4 percent if the affected child is male, and ≥30 percent if there are two or more affected children [36,42,43].
Siblings of children with ASD may have symptoms of ASD even if they do not meet criteria for diagnosis of ASD (sometimes called the "broad ASD phenotype"). In observational studies, symptoms of ASD or associated neurodevelopmental abnormalities were more common among siblings of ASD than siblings of children without ASD [39,44-50].
Associated conditions and syndromes — A number of neurodevelopmental conditions and genetic syndromes are associated with ASD [1]. Approximately 33 to 45 percent of patients with ASD have ID, as many as 50 percent have attention deficit hyperactivity disorder, and as many as 30 percent have epilepsy [16,22,51-53]. The risk of epilepsy is increased in patients with more severe ID [38].
Up to 25 percent of cases of ASD are associated with a genetic cause, many of which have well-characterized clinical features (eg, tuberous sclerosis complex [TSC], valproate embryopathy, 15q chromosome duplication) [54-59]. Associated syndromes are more common in patients with global developmental delay or ID. Any genetic syndrome that has been associated with ID can also be associated with ASD (eg, Down syndrome) [60]. Genetic diagnoses commonly associated with ASD include (table 2) [22,38,54,61,62]:
●Tuberous sclerosis complex – TSC is an inherited neurocutaneous disorder that is characterized by the development of variety of benign tumors in multiple organs. Associated clinical features include hypopigmented macules (picture 1A-B), angiofibromas (picture 2), shagreen patches (picture 3), seizures, and cognitive deficits. Approximately 40 percent of patients with TSC also have ASD; however, only 0.4 to 4 percent of patients with ASD have TSC [63-66]. Patients with comorbid TSC and ASD often have epilepsy [63,65,67,68]. (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis".)
●Fragile X syndrome – Fragile X syndrome is an X-linked disorder that is often associated with ID. Characteristic features of the classic phenotype include a long, narrow face, prominent forehead and chin, large ears, testicular enlargement in adolescence, macrocephaly, arched palate, and hyperextensible joints. In a systematic review, 30 percent of males with fragile X syndrome had features of ASD [66]. However, fragile X syndrome is rarely found in patients with ASD [69-71]. (See "Fragile X syndrome: Clinical features and diagnosis in children and adolescents".)
●Chromosome 15q11-q13 duplication syndrome – Chromosome 15 q11-q13 duplication syndrome is characterized by hypotonia, joint laxity, global (especially motor) developmental delays, seizures, speech delay, social deficits, stereotypies, and a variable pattern of mild facial dysmorphisms [72,73]. 15q11-q13 duplication has been reported in approximately 1 to 2 percent of children with ASD, usually those with moderate to profound ID [61,74-77]. (See "Microduplication syndromes", section on '15q11-13 duplication syndrome'.)
●Angelman syndrome – Angelman syndrome is a neurodevelopmental disorder characterized by severe ID, postnatal microcephaly, and movement or balance problems. It is caused by absence of the maternally inherited copy of the UBE3A gene, which maps to chromosome 15q11-q13. In a systematic review, 34 percent of patients with Angelman syndrome had ASD [66]. (See "Microdeletion syndromes (chromosomes 12 to 22)", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'.)
●Rett syndrome – Classic Rett syndrome occurs almost exclusively in females. It is characterized by loss of speech, replacement of purposeful hand movement with stereotypic hand movement, gait abnormalities, and an abnormal respiratory pattern. In a systematic review, approximately 60 percent of females with Rett syndrome had phenomenology of ASD [66]. (See "Rett syndrome: Genetics, clinical features, and diagnosis".)
●Cohen syndrome – Clinical features of Cohen syndrome include characteristic facial features (eg, thick hair and eyebrows, wave-shaped palpebral fissures, broad nasal tip, short or smooth philtrum), microcephaly, poor weight gain in infancy, truncal obesity in adolescence, hypotonia, developmental delay, neutropenia, and joint hypermobility [78]. In a systematic review, approximately 54 percent of patients with Cohen syndrome had phenomenology of ASD [66].
●Cornelia de Lange syndrome – Cornelia de Lange syndrome is characterized by distinctive facial features (microcephaly, synophrys, highly arched eyebrows, anteverted nares), prenatal onset growth delay, hirsutism, and upper-limb reduction deficits [79]. Associated findings include hearing impairment, myopia, cardiac septal defects, gastrointestinal dysfunction, and genitourinary abnormalities. In a systematic review, approximately 43 percent of patients with Cornelia de Lange syndrome had phenomenology of ASD [66].
●Neurofibromatosis type 1 – Neurofibromatosis type 1 (NF1) is characterized by multiple café-au-lait macules (picture 4), axillary and/or inguinal freckling, Lisch nodules (iris hamartomas), and neurofibromas (picture 5). In a systematic review, approximately 18 percent of patients with NF1 had phenomenology of ASD [66]. (See "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'.)
●Down syndrome – Down syndrome is characterized by a variety of dysmorphic features (eg, upslanting palpebral fissures, epicanthic folds, brachycephaly), congenital malformations (eg, transverse palmar crease), ID, and other medical conditions (eg, cardiovascular disease, gastrointestinal abnormalities, endocrine disorders). In a systematic review, approximately 16 percent of patients with Down syndrome had phenomenology of ASD [66]. (See "Down syndrome: Clinical features and diagnosis".)
●Noonan syndrome – Noonan syndrome is a clinically and genetically heterogeneous condition that is associated with short stature and congenital heart disease (most often pulmonic stenosis) and delayed development. In a systematic review, approximately 15 percent of patients with Noonan syndrome had phenomenology of ASD [66]. (See "Noonan syndrome", section on 'Clinical manifestations'.)
●Williams-Beuren syndrome – Williams-Beuren syndrome is a multisystemic genetic disorder with variable phenotypic expression that is associated with "elfin" facies, systemic arterial stenosis (most often supravalvular aortic stenosis), short stature, genitourinary abnormalities, and impaired cognition and development. In a systematic review, approximately 12 percent of patients with Williams-Beuren syndrome had phenomenology of ASD [66]. (See "Williams syndrome", section on 'Clinical manifestations'.)
●DiGeorge (22q11.2 deletion) syndrome – The classic presentation of DiGeorge syndrome includes conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia; however, the phenotype is variable (table 3). In a systematic review, approximately 11 percent of patients with 22q11.2 deletion syndrome had phenomenology of ASD [66]. (See "DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis".)
●PTEN (phosphatase and tensin homolog gene)-associated macrocephaly syndromes; PTEN-associated macrocephaly syndromes include:
•Macrocephaly/autism syndrome – Clinical features of macrocephaly/autism syndrome include postnatal macrocephaly, broad forehead, frontal bossing, long philtrum, depressed nasal bridge, and ID.
•Cowden/Bannayan-Riley-Ruvalcaba syndrome – Clinical features of Cowden syndrome include macrocephaly, birdlike facies, hypoplastic mandible and maxilla, cataract, microstomia, high-arched palate, pectus excavatum, genitourinary anomalies, skin tags, lipomas, and penile macules.
●CHARGE syndrome – CHARGE syndrome is characterized by coloboma of the eye, heart defects, choanal atresia, growth retardation, genitourinary anomalies, and ear abnormalities. As many as 50 percent of affected patients have ASD [22,66].
●Joubert syndrome – Joubert syndrome is a heterogeneous syndrome characterized by hypoplasia of the cerebellar vermis, neurologic symptoms (eg, dysregulation of breathing pattern, developmental delay), retinal dystrophy, and renal anomalies. Approximately 40 percent of patients with Joubert syndrome also have ASD [22]. (See "Clinical manifestations, diagnosis, and treatment of nephronophthisis", section on 'Joubert syndrome'.)
●Smith-Lemli-Opitz syndrome – Smith-Lemli-Opitz syndrome is an autosomal recessive disorder of cholesterol biosynthesis [38]. Clinical features include postnatal microcephaly, soft cleft palate/bifid uvula, micrognathia, low-set posteriorly rotated ears, poor weight gain, syndactyly of the second and third toes, abnormal genitalia, ID, hypotonia, and autistic features (eg, deficits in social interaction and communication, repetitive and stereotyped behaviors) [80,81]. In one case series, 10 to 12 of 14 children with Smith-Lemli-Opitz syndrome met criteria for ASD [80].
●Timothy syndrome – Timothy syndrome is characterized by syndactyly, congenital heart disease, multiorgan dysfunction, and cognitive abnormalities. As many as 70 percent of patients with Timothy syndrome also have ASD [22].
Genetic syndromes that are not well characterized clinically may account for as many as 20 percent of cases of ASD [54]. These syndromes are characterized by incomplete penetrance and variable expressivity – which makes them difficult to identify clinically. Although there is some overlap with clinically defined syndromes, examples of such syndromes include chromosomal variations (eg, isodicentric 15q), ASD-associated copy-number variants (eg, 16p11.2 deletions or duplications), and pathogenic variants of ASD-risk genes (eg, CHD8 [chromosome helicase DNA binding protein 8]).
PATHOGENESIS
Genetic factors — The pathogenesis of ASD is incompletely understood. The general consensus is that ASD is caused by genetic factors that alter brain development, specifically neural connectivity, thereby affecting social communication development and leading to restricted interests and repetitive behaviors [82-85]. This consensus is supported by the "epigenetic theory," in which an abnormal gene is turned "on" early in fetal development and affects the expression of other genes without changing their primary DNA sequence [86,87]. In a multinational, population-based cohort study including more than 2 million children, approximately 1 percent of whom were diagnosed with ASD by age 16 years, the estimated median heritability of ASD was 81 percent (95% CI 73-86 percent) [88]. (See "Principles of epigenetics".)
Given the complexity of ASD and the diversity of clinical manifestations, it is likely that interactions between multiple genes or gene combinations are responsible for ASD and that epigenetic factors and exposure to environmental modifiers contribute to the variable expression [89-94]. ASDs have been associated with polygenic variants, single nucleotide variants, copy number variants, rare inherited variants, and noncoding variants [54,84,94-97]. (See "Genetics: Glossary of terms" and 'Associated conditions and syndromes' above.)
A strong genetic contribution to the development of ASD is supported by the unequal sex distribution, increased prevalence in siblings, high concordance in monozygotic twins, and increased risk of ASD with increased relatedness [37,49,89,90,94,98-102]. In a large population-based study, the cumulative risk of ASD by age 20 years was approximately 3 percent for cousins, 7 percent for paternal half-siblings, 9 percent for maternal half-siblings, 13 percent for full siblings and dizygotic twins, and 59 percent for monozygotic twins [37]. (See 'Male-to-female ratio' above and 'Rate in siblings' above.)
Although male predominance suggests X-linkage, male-to-male transmission in a number of families excludes X-linkage as the only mode of inheritance [89,103]. The prevalence among siblings of patients with ASD is higher than the prevalence in the general population [89,104-106] but much lower than would be expected for single-gene diseases [89]. (See 'Male-to-female ratio' above and 'Rate in siblings' above.)
The correlation between clinical phenotypes and specific genetic profiles continues to be investigated. Although linkage studies and whole exome sequencing have identified many genetic variations predisposing to ASD [42,54,107], no individual variation accounts for >1 percent of cases of ASD and no specific mutation is unique to ASD [38]. (See 'Associated conditions and syndromes' above.)
Neurobiologic factors — Neuroimaging, electrophysiology, and autopsy studies in patients with ASD suggest that brain abnormalities, particularly atypical neural connectivity, play an important role in the development of ASD [22,108].
Children with ASD may have accelerated head growth during infancy and increased overall brain size [109,110]. (See "Autism spectrum disorder: Clinical features", section on 'Macrocephaly'.)
Compared with individuals without ASD, individuals with ASD have different total and regional gray and white matter volumes, sulcal and gyral anatomy, brain chemical concentrations, neural networks, cortical structure and organization, and brain lateralization [111-118]. Cortical changes appear to result from abnormal neuronal differentiation during prenatal development [117]. Individuals with ASD use different patterns of connectivity, cognitive strategies, and brain areas to process information during tasks requiring social attribution (eg, faces, eye gaze, speech) and social and nonsocial rewards than individuals without ASD [119-130].
Parental age — Advanced parental age (both paternal and maternal) has been associated with an increased risk of having a child with ASD [131-137]. The age comparisons vary from study to study but typically range from ≥30 to 35 years versus <30 years for mothers and ≥40 years versus <30 years for fathers. The association between advanced parental age and increased risk of having a child with ASD is perhaps related to de novo spontaneous mutations and/or alterations in genetic imprinting [138]. (See "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'.)
Environmental and perinatal factors — Environmental factors include toxic exposures, teratogens, perinatal insults, and prenatal infections. They account for few cases of ASD but may constitute a "second-hit," modulating existing genetic factors predisposing to ASD [38,84,139]. The effects of environmental exposures appear to depend on the timing and duration of exposure, concentration of the toxin, mechanism of action, and distribution in the central nervous system.
A meta-analysis of 40 heterogeneous observational studies of perinatal and neonatal risk factors for autism found little evidence to implicate any single factor in the etiology of autism [140]. However, there was some evidence to suggest that the broad class of conditions that compromise perinatal and neonatal health (eg, abnormal presentation, low birth weight, meconium aspiration) may increase the risk. A subsequent meta-analysis of observational studies supports an increased risk of ASD in preterm infants [141]. Subsequent observational studies also suggest that maternal conditions (eg, diabetes, obesity, hypertension, preeclampsia) are associated with increased risk of ASD [142-147].
Maternal medication use during pregnancy — The potential role of maternal medication use during pregnancy in the development of ASD is discussed separately. (See "Risks associated with epilepsy during pregnancy and postpartum period", section on 'Neurodevelopmental risks of AEDs' and "Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Risk of psychopathology in the offspring", section on 'Autism'.)
Lack of association with immunizations — Epidemiologic evidence does not support an association between immunizations and ASD. (See "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor".)
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
●Basics topics (see "Patient education: Autism spectrum disorder (The Basics)" and "Patient education: Asperger syndrome (The Basics)")
●Beyond the Basics topic (see "Patient education: Autism spectrum disorder (Beyond the Basics)")
SUMMARY
●Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, or activities. Symptoms become apparent when social demands exceed limited capacities. Severity is determined by functional impairment and can be critical in the ability to access services. (See 'Terminology' above.)
●Estimates of prevalence vary with study methodology and the population that is evaluated and range from 1 in 40 to 1 in 500. The prevalence of ASD has increased over time, particularly since the late 1990s, primarily as a result of changes in case definition and increased awareness. In the United States, national surveillance suggests a prevalence of approximately 1 in 40 to 1 in 60. (See 'Prevalence' above.)
●Intellectual disability, attention deficit hyperactivity disorder, and epilepsy are common in children with ASD. ASD is more common among children with certain genetic conditions than in the general population (table 2). These conditions include tuberous sclerosis complex, fragile X syndrome, chromosome 15q11-13 duplication syndrome, Angelman syndrome, Rett syndrome, Down syndrome, Cohen syndrome, Cornelia de Lange syndrome, Neurofibromatosis type 1, Noonan syndrome, Williams-Beuren syndrome, DiGeorge (22q11.2 deletion) syndrome, PTEN-associated macrocephaly syndrome, CHARGE syndrome, Joubert syndrome, Smith-Lemli-Opitz syndrome, and Timothy syndrome. (See 'Associated conditions and syndromes' above.)
●The pathogenesis of ASD is incompletely understood. The general consensus is that ASD is caused by genetic factors that alter brain development resulting in the neurobehavioral phenotype. Environmental and perinatal factors account for few cases of ASD but may modulate underlying genetic factors. (See 'Pathogenesis' above.)
●The overwhelming majority of epidemiologic evidence does not support an association between immunizations and ASD. (See "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor".)
1 : American Psychiatric Association. Autism spectrum disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.50.
2 : World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. www.who.int/classifications/icd/en/bluebook.pdf (Accessed on March 28, 2018).
3 : World Health Organization. Classifications. Available at: http://www.who.int/classifications/icd/en/ (Accessed on July 03, 2018).
4 : Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP).
5 : Prevalence of autistic spectrum disorder in children attending mainstream schools in a Welsh education authority.
6 : Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort.
7 : Prevalence and incidence of autism spectrum disorders among national health insurance enrollees in Taiwan from 1996 to 2005.
8 : Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children.
9 : Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey.
10 : Prevalence of autism spectrum disorders in a total population sample.
11 : Prevalence of Autism Spectrum Disorder Among US Children and Adolescents, 2014-2016.
12 : Epidemiology of autism in adults across age groups and ability levels.
13 : Cumulative Incidence of Autism Into Adulthood for Birth Cohorts in Denmark, 1980-2012.
14 : The Prevalence of Parent-Reported Autism Spectrum Disorder Among US Children.
15 : Prevalence and Treatment Patterns of Autism Spectrum Disorder in the United States, 2016.
16 : Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018.
17 : Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018.
18 : Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years.
19 : Trends in Autism Spectrum Disorder Diagnoses in Japan, 2009 to 2019.
20 : Comparison of 2 Case Definitions for Ascertaining the Prevalence of Autism Spectrum Disorder Among 8-Year-Old Children.
21 : Systematic review of prevalence studies of autism spectrum disorders.
22 : Autism.
23 : Epidemiology of pervasive developmental disorders.
24 : The epidemiology of autistic spectrum disorders: is the prevalence rising?
25 : The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education.
26 : The epidemiology and global burden of autism spectrum disorders.
27 : The epidemiology and global burden of autism spectrum disorders.
28 : The changing prevalence of autism in California.
29 : The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study.
30 : Differences among states in the identification of autistic spectrum disorders.
31 : Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder.
32 : Autism prevalence trends over time in Denmark: changes in prevalence and age at diagnosis.
33 : The rise in autism and the role of age at diagnosis.
34 : What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis.
35 : Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017.
36 : Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study.
37 : The familial risk of autism.
38 : Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.
39 : Risk of Psychiatric and Neurodevelopmental Disorders Among Siblings of Probands With Autism Spectrum Disorders.
40 : Sibling recurrence and the genetic epidemiology of autism.
41 : Association of Sex With Recurrence of Autism Spectrum Disorder Among Siblings.
42 : Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions.
43 : Genetic counseling in autism and pervasive developmental disorders.
44 : Cognitive and verbal abilities of 24- to 36-month-old siblings of children with autism.
45 : Broader autism phenotype: evidence from a family history study of multiple-incidence autism families.
46 : Gaze-fixation, brain activation, and amygdala volume in unaffected siblings of individuals with autism.
47 : Developmental trajectories in siblings of children with autism: cognition and language from 4 months to 7 years.
48 : The development of young siblings of children with autism from 4 to 54 months.
49 : Sibling Recurrence Risk and Cross-aggregation of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
50 : Language and reading abilities of children with autism spectrum disorders and specific language impairment and their first-degree relatives.
51 : The co-occurrence of autism and attention deficit hyperactivity disorder in children - what do we know?
52 : The co-occurrence of epilepsy and autism: A systematic review.
53 : Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample.
54 : Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach.
55 : Pervasive developmental disorders in preschool children.
56 : Pervasive developmental disorders in preschool children: confirmation of high prevalence.
57 : Autism and medical disorders: a review of the literature.
58 : Etiologic yield of autistic spectrum disorders: a prospective study.
59 : Autism and known medical conditions: myth and substance.
60 : Prevalence of autism and attention-deficit-hyperactivity disorder in Down syndrome: a population-based study.
61 : Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society.
62 : Specific genetic disorders and autism: clinical contribution towards their identification.
63 : Autism and tuberous sclerosis.
64 : Study of the relationship between tuberous sclerosis complex and autistic disorder.
65 : Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex.
66 : Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis.
67 : Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study.
68 : Neuropsychiatric aspects of tuberous sclerosis.
69 : Do the data really support ordering fragile X testing as a first-tier test without clinical features?
70 : Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder?
71 : Fragile X testing as a second-tier test.
72 : The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders.
73 : The behavioral phenotype of the idic(15) syndrome.
74 : Autism or atypical autism in maternally but not paternally derived proximal 15q duplication.
75 : Three probands with autistic disorder and isodicentric chromosome 15.
76 : Brief report: duplication of chromosome 15q11-13 in two individuals with autistic disorder.
77 : Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13.
78 : Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13.
79 : Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13.
80 : The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome.
81 : Smith-Lemli-Opitz syndrome and autism spectrum disorder.
82 : Two new theories of autism: hyper-systemising and assortative mating.
83 : Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan.
84 : The Emerging Clinical Neuroscience of Autism Spectrum Disorder: A Review.
85 : Genetics of autism spectrum disorders.
86 : Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders.
87 : Loud and clear evidence for gene silencing by epigenetic mechanisms in autism spectrum and related neurodevelopmental disorders.
88 : Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort.
89 : The genetics of autism.
90 : Genetic heritability and shared environmental factors among twin pairs with autism.
91 : Autism spectrum disorders: molecular genetic advances.
92 : Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.
93 : Whole-genome sequencing of quartet families with autism spectrum disorder.
94 : Genetic research in autism spectrum disorders.
95 : Progress in the genetics of autism spectrum disorder.
96 : Whole-genome deep-learning analysis identifies contribution of noncoding mutations to autism risk.
97 : Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder.
98 : Characteristics and concordance of autism spectrum disorders among 277 twin pairs.
99 : The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood.
100 : Heritability of Autism Spectrum Disorder in a UK Population-Based Twin Sample.
101 : The Heritability of Autism Spectrum Disorder.
102 : Recurrence Risk of Autism in Siblings and Cousins: A Multinational, Population-Based Study.
103 : NPY1, a BTB-NPH3-like protein, plays a critical role in auxin-regulated organogenesis in Arabidopsis.
104 : A case-control family history study of autism.
105 : Complex segregation analysis of autism.
106 : A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals.
107 : Autism genetics - an overview.
108 : MRI findings in 77 children with non-syndromic autistic disorder.
109 : Neuron number and size in prefrontal cortex of children with autism.
110 : Early brain development in infants at high risk for autism spectrum disorder.
111 : Advances in autism neuroimaging research for the clinician and geneticist.
112 : Neuroanatomical substrates of social cognition dysfunction in autism.
113 : Structural MRI in autism spectrum disorder.
114 : Patches of disorganization in the neocortex of children with autism.
115 : Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.
116 : Structural Gray Matter Differences During Childhood Development in Autism Spectrum Disorder: A Multimetric Approach.
117 : The neuropathology of the autism spectrum disorders: what have we learned?
118 : Deficits in mesolimbic reward pathway underlie social interaction impairments in children with autism.
119 : Abnormal cortical voice processing in autism.
120 : The brain response to personally familiar faces in autism: findings of fusiform activity and beyond.
121 : Emotional attribution in high-functioning individuals with autistic spectrum disorder: a functional imaging study.
122 : Neural correlates of facial affect processing in children and adolescents with autism spectrum disorder.
123 : Neural mechanisms of imitation and 'mirror neuron' functioning in autistic spectrum disorder.
124 : Gaze fixation and the neural circuitry of face processing in autism.
125 : Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age.
126 : Event-related brain potentials reveal anomalies in temporal processing of faces in autism spectrum disorder.
127 : Abnormal activation of face processing systems at early and intermediate latency in individuals with autism spectrum disorder: a magnetoencephalographic study.
128 : Delayed automatic detection of change in speech sounds in adults with autism: a magnetoencephalographic study.
129 : Auditory spatial localization and attention deficits in autistic adults.
130 : Evaluation of the Social Motivation Hypothesis of Autism: A Systematic Review and Meta-analysis.
131 : Prenatal risk factors for autism: comprehensive meta-analysis.
132 : Risk of autism and increasing maternal and paternal age in a large north American population.
133 : Advanced parental age and the risk of autism spectrum disorder.
134 : Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis.
135 : Parental Age and Differential Estimates of Risk for Neuropsychiatric Disorders: Findings From the Danish Birth Cohort.
136 : Autism risk associated with parental age and with increasing difference in age between the parents.
137 : Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies.
138 : Rate of de novo mutations and the importance of father's age to disease risk.
139 : Epigenetics of autism-related impairment: copy number variation and maternal infection.
140 : Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis.
141 : Prevalence of Autism Spectrum Disorder in Preterm Infants: A Meta-analysis.
142 : Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis.
143 : Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders.
144 : Association of maternal diabetes with autism in offspring.
145 : Association of Maternal Diabetes With Autism in Offspring.
146 : Maternal Type 1 Diabetes and Risk of Autism in Offspring.
147 : Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder.